What is Gemcitabine HCl Market?
Gemcitabine HCl is a white to off-white solid. It is soluble in water, sparingly soluble in methanol, and practically insoluble in ethanol and polar organic solvents. Gemcitabine HCl is the antimetabolite antineoplastic with synthetic pyrimidine nucleoside. It replaces cytidine during DNA replication. Because of this growth in tumor growth, no new nucleosides can be bound to the “faulty” nucleoside, which leads to apoptosis in tumor cells. It is the FDA cleared compound that is sold under the brand name "Gemzar" (IV formulation). It can be used in combination with other oncological agents such as paclitaxel, cisplatin, and others. Gemcitabine is used in combination with cisplatin to treat a type of lung cancer (non-small cell lung cancer; NSCLC) that has spread to other parts of the body and cannot be treated by surgery. Gemcitabine is also used to treat pancreatic cancer that has spread to other parts of the body and has not improved or worsened after treatment with another medicine. Gemcitabine belongs to a class of drugs called antimetabolites. It slows down or stops cancer cells from growing in your body.
The market study is being classified by Type (Branded and Generic) and major geographies with country level break-up.
Eli Lilly and Company (United States), Sun Pharmaceutical Industries Ltd. (India), Pfizer Inc. (United States), Cipla Inc. (India), Teva Pharmaceutical Industries Ltd. (Israel), Emcure Pharmaceuticals (India), Accord Healthcare (United States), Mylan N.V. (United States), Dr. Reddy’s Laboratories Ltd. (India) and Fresenius Kabi USA (United States) are some of the key players profiled in the study.
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Vendors will contribute to the maximum growth of Global Gemcitabine HCl market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Gemcitabine HCl market by Type, Application and Region.
On the basis of geography, the market of Gemcitabine HCl has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Growing Cases of Cancer Especially In Females Such As Breast and Ovarian Cancer
- Increased Advancement in the Treatment of Cancer
- Increased Awareness Related To Healthcare Insurance Policy
- Rise in Immune System Diseases Worldwide
- Growing Burden of Cancer
- Rising Prevalence of Cancer and Related Disorders in Worldwide and Emerging Markets
- Increasing Initiatives Taken By the Pharmaceutical Organizations to Generate Novel Formulation
- High Cost of Treatment & Chemotherapy
- Stringent Regulatory Framework
- Adverse Effect after the Treatment
- Increasing Research & Development Activities
- Increasing Initiatives Taken By the Government & Pharmaceutical Organizations to Spread Awareness and Presence of Generic Manufacturer
- Presence and Availability of Global Brands and Their Challenges Faced Due to Large or Scarce Competition from Local and Domestic Brands
Key Target AudienceManufacturers of Gemcitabine HCl, Suppliers of Gemcitabine HCl, Wholesalers, Distributors and Retailers of Gemcitabine HCl, Pharmaceutical Industry, Regulatory Bodies and Governmental Bodies
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase